In the fast-growing world of SARMs (Selective Androgen Receptor Modulators), one compound generating significant buzz is ACP-105. Often called one of the newest and strongest SARMs, ACP-105 is marketed as delivering rapid muscle gains, fat loss support, and bone density improvements—with fewer side effects than anabolic steroids.
But does ACP-105 actually live up to the hype? In this ultimate reference guide, we break down everything you need to know about ACP-105—including dosages, half-life, results, side effects, comparisons to other SARMs, and what clinical data (and users) really say.
What is ACP-105?
ACP-105 is a non-steroidal SARM developed as a potential treatment for muscle wasting and osteoporosis. Like other SARMs, it binds to androgen receptors in muscle and bone, triggering anabolic effects. Unlike steroids, ACP-105 does not convert to estrogen or DHT, meaning reduced risks of gynecomastia (man boobs), hair loss, or prostate enlargement.
ACP-105 for bodybuilding has gained popularity because it’s reported to deliver fast lean muscle growth while minimizing side effects—though research is still very limited.
ACP-105 Half-Life
One of the most commonly searched questions is: What is the half-life of ACP-105?
-
Lab data suggests ACP-105 has a short half-life of 4–6 hours, based on in vitro hepatocyte studies.
-
This likely means split dosing (AM/PM) is required for stable blood levels.
-
Unlike Ostarine (MK-2866) or LGD-4033 (Ligandrol), which have half-lives of 24+ hours, ACP-105 may need multiple doses daily.
⚠️ Note: These numbers are not yet confirmed in large-scale human trials, making real-world pharmacology uncertain.
ACP-105 Dosage Guidelines (Reported in Bodybuilding Communities)
Since no official medical dosing exists, any ACP-105 dosage recommendations come from community use:
-
Beginner dosage: 5–10 mg per day
-
Intermediate dosage: 10–15 mg per day
-
Advanced dosage: 15–20 mg per day
-
Cycle length: 6–8 weeks (due to suppression risks)
Because of the short half-life of ACP-105, users often split their dose into two servings daily.
⚠️ Again: These figures are anecdotal. ACP-105 is not FDA-approved, and all human use carries unknown risks.
ACP-105 Results — Muscle, Fat Loss & Performance
Reported Benefits of ACP-105:
-
Lean Muscle Growth: Users report noticeable muscle gains in 4–6 weeks, sometimes faster than Ostarine.
-
Strength Gains: Enhanced performance in lifts and endurance sessions.
-
Faster Recovery: Shorter rest times between workouts.
-
Fat Loss Support: Promotes lean muscle retention during calorie deficits.
-
Bone Health: Preclinical studies show bone density improvements, suggesting potential medical applications.
Example Anecdotal Feedback:
-
Some users claim 4–6 lbs of lean muscle gain in one cycle.
-
Others note improved vascularity and definition when combined with cutting protocols.
-
Bloodwork logs often show testosterone suppression—requiring PCT (Post Cycle Therapy) to restore natural levels.
ACP-105 Side Effects
Is ACP-105 safe? This is one of the top questions asked. Like all SARMs, ACP-105 carries risks and side effects:
-
Testosterone Suppression: Nearly all SARM cycles, including ACP-105, reduce natural T levels.
-
Fatigue or Low Libido: Commonly reported when suppression occurs.
-
Liver Stress: ACP-105 appears less hepatotoxic than oral steroids, but mild liver enzyme elevation has been reported.
-
Cholesterol Changes: Lower HDL and increased LDL are possible.
-
Unknown Long-Term Safety: No long-term human trials exist.
⚠️ Bottom line: ACP-105 is not risk-free. If used, regular bloodwork is essential.
ACP-105 vs Other SARMs
When bodybuilders compare SARMs, they often ask: Is ACP-105 stronger than Ostarine or LGD-4033?
-
ACP-105 vs Ostarine (MK-2866):
-
Ostarine is mild and beginner-friendly.
-
ACP-105 is more anabolic and delivers faster gains, but with higher suppression.
-
-
ACP-105 vs Ligandrol (LGD-4033):
-
Ligandrol is known for massive bulking effects.
-
ACP-105 offers a middle ground: strong gains but with less water retention.
-
-
ACP-105 vs RAD-140 (Testolone):
-
RAD-140 is the most potent SARM.
-
ACP-105 is slightly weaker but may carry fewer side effects.
-
ACP-105 Clinical Studies
So far, only preclinical animal studies and limited Phase I human testing exist:
-
Animal Models: Increased lean mass and bone density in rats, with minimal prostate stimulation.
-
Human Phase I (reported): Showed tolerability and slight muscle gain in healthy men. Testosterone suppression was still noted.
More research is needed before ACP-105 can be considered safe for medical or performance use.
ACP-105 Bloodwork & Community Logs
Bodybuilding forums and Reddit logs often share ACP-105 blood test results. Common findings include:
-
Suppressed testosterone (low total/free T).
-
Elevated liver enzymes in longer cycles.
-
Altered lipid profiles (low HDL, high LDL).
Some users claim fast strength increases, but most also note the need for PCT protocols (Nolvadex, Clomid, Enclomiphene) to recover.
Legal Status of ACP-105
-
Not FDA-approved for human use.
-
Classified as a research chemical only.
-
Banned by WADA (World Anti-Doping Agency).
-
Marketed supplements often mislabeled or underdosed, raising quality concerns.
Key SEO Takeaways (For Searchers)
-
What is ACP-105? → A potent research SARM for muscle and bone.
-
What is the half-life of ACP-105? → Estimated 4–6 hours.
-
What is the dosage for ACP-105? → 5–20 mg daily (anecdotal).
-
Is ACP-105 safe? → Limited data, risks include testosterone suppression and liver/lipid changes.
-
ACP-105 results? → Users report fast lean gains and strength, but suppression is almost guaranteed.
Final Thoughts on ACP-105
ACP-105 is often marketed as the next big SARM—delivering strong muscle and performance gains without steroid-level side effects. But the reality is that research is limited, risks are real, and long-term safety remains unknown.
For athletes and bodybuilders, the short half-life, strong anabolic profile, and suppression risks make ACP-105 intriguing but also dangerous. As with all SARMs, responsible use, bloodwork, and caution are non-negotiable.
